On the evening of May 29, Jimin HealthManagement Co., Ltd. (hereinafter referred to as " Jimin Health ") issued an announcement that on May 28, 2025, the company's Boao International Hospital and Guangzhou Dabo Biological ProductsCo., Ltd. (hereinafter referred to as "Dabao Bio") signed the "Strategic Cooperation Framework Agreement".

Founded in May 2001 and headquartered in Huangpu District, Guangzhou, Dabo Bio is a national high-tech enterprise focusing on anti-tumor gene therapy, immune cell therapy and regenerative medicine.

The announcement shows that the "Strategic Cooperation Framework Agreement" mainly covers the following four aspects: first, to promote the clinical research and translational application of new biomedical technologies such as cell and gene therapy; second, to achieve the improvement of scientific research conditions and resource sharing; third, to carry out talent exchange and training; and fourth, to promote the coordinated development of the industrial chain.

It is reported that the development of cell therapy drugs is one of the key layout and investment directions of Jimin Health . The signing of this agreement aims to take advantage of local policy advantages, strengthen the complementarity of technology and talents through external cooperation, drive R&D innovation with clinical needs, expand the layout of cell and gene therapy pipelines, and create a "R&D-clinical-commercialization" vertical integration model, which is of great strategic significance to the company's future development.

https://finance.eastmoney.com/a/202505293418098417.html